Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
Companies Commented On
- Acadia Pharmaceuticals Inc.
- Arena Pharmaceuticals Inc.
- BioDelivery Sciences International Inc.
- Catalyst Pharmaceutical Partners Inc.
- CTI BioPharma
- Inovio Pharmaceuticals Inc.
- Orexigen Therapeutics Inc.
- Roche Holding AG
- Threshold Pharmaceuticals Inc.
- Vivus Inc.
Dr. Charles Duncan is a managing director and senior research analyst at Piper Jaffray & Co. focusing on small- and mid-cap emerging growth biotechnology companies. Duncan brings more than 18 years of sellside experience and has been recognized by industry sources, including the StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis. He is a graduate of the University of Wisconsin and holds a doctorate in neuropharmacology from the University of Colorado.
Piper Jaffray's Charles Duncan Addresses Pot Shots (6/26/14) Early-stage biotech is a risky investment, but some bets are safer than others. Inovio Pharmaceuticals Inc. is doing high-stakes experimental work in both preventive and therapeutic medicine, addressing HIV, cancers and pre-cancers. The company's lead clinical program is in Phase 2 and a data readout is imminent, which has made the stock both volatile and an easy target for critics. In this interview with The Life Sciences Report, Senior Biotechnology Analyst and Managing Director Charles Duncan of Piper Jaffray & Co. addresses some of the criticisms that overhang the stock.
Charles Duncan: 2014 Is for Careful Stock Pickers, Not Dart Throwers (4/24/14) Veteran Senior Biotechnology Analyst Charles Duncan of Piper Jaffray & Co. sees platform companies as the perfect way to play a consolidating market. We've had a big run in biotech, and Duncan believes now is the time to identify, through careful diligence, companies that can advance in a more temperate market. In this interview with The Life Sciences Report, Duncan discusses five biotech and specialty pharma innovators poised to produce therapies enabled by versatile and scalable technology platforms that target multiple disease indications.
"INO's stock could hit double digits pretty easily, in terms of its trading range, with a good outcome from the Phase 2 VGX-3100 study." (6/26/14) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan Moreá>
"THLD's soft-tissue sarcoma study should read out at the end of 2015; that could be a very exciting time." (4/24/14) Threshold Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan Moreá>
"The Phase 2 trial for VGX-3100 could be a major clinical validation of the power of INO's broadly applicable platform." (4/24/14) Inovio Pharmaceuticals Inc. - The Life Sciences Report interview with Charles Duncan Moreá>
"INO's idea of using DNA, which is simple to make and cost-effective, to drive the body's natural immune response is just fascinating." (3/25/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Jill Wahleithner Moreá>